What changed for Hepatitis C
A plain English summary of what recently moved in the public data Voxsanity tracks for Hepatitis C. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 37 to 33 (-4)
- Trials on record 2,030 to 2,022 (-8)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Hepatitis C in July 2026. Voxsanity tracks 4 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 191 trials tracked for Hepatitis C that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05376371 · results posted 17 November 2025
According to the results reported on ClinicalTrials.gov, this trial tested a program called CJC-TraC, which used nurse case managers to support people with chronic (long-term) health conditions as they were released from prison. The program involved sessions with a nurse before release and follow-up phone calls after release. A total of 219 people were enrolled in the study, and 209 of them completed the full trial period. There was only one group — everyone received the CJC-TraC intervention, so the trial was designed to assess whether the program was practical to run and acceptable to partic...
-
NCT06922643 · results posted 29 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 100 people who had Hepatitis C (a viral liver infection) and were treated with a medicine called Pegnano (peginterferon alfa-2a). Of the 100 who started, 97 completed the study and 3 did not. The trial was measuring whether the Hepatitis C virus became undetectable in participants' blood at several points during and after treatment — including at 4 weeks, 12 weeks, at the end of treatment, and 24 weeks after treatment finished. The main goal was to see how many participants had no detectable virus in their blood 24 we...
-
NCT04903626 · results posted 6 April 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 286 people, all of whom received a combination treatment called glecaprevir/pibrentasvir for hepatitis C. Of those who started, 278 completed the trial and 8 did not finish. The trial was primarily measuring how many participants had no detectable hepatitis C virus in their blood 12 weeks after finishing treatment — a result known as SVR12, which simply means the virus could no longer be measured in the blood at that point in time. The reported data shows that 96.2% of all participants who started treatment had no de...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03362476 · results posted 9 January 2025
According to the results reported on ClinicalTrials.gov, this trial involved 200 women living with HIV who drink alcohol — 98 in one group and 102 in the other. One group received a computer-based alcohol reduction program combined with a brief counselling session delivered by a clinician, while the other group received only the clinician-delivered counselling session (described as the standard of care). The trial was measuring alcohol use, HIV-related health indicators, and liver health over a period of up to nine months. The reported data shows that for the main outcome — a urine test calle...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04515797 · results posted 3 December 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 2 participants, both of whom completed the study. The trial was looking at the use of a direct-acting antiviral medication (a type of drug that targets the hepatitis C virus) in people who had received a kidney transplant from a donor who had hepatitis C. The main thing the trial was measuring was whether participants had no detectable hepatitis C virus in their blood 12 weeks after finishing their course of treatment. The reported data shows that both participants (2 out of 2) had undetectable hepatitis C virus leve...
-
NCT02933970 · results posted 2 December 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 156 participants in total (52 in each of three groups). The trial was looking at care for hepatitis C — a liver infection caused by a virus — and compared two approaches: "usual care" (standard in-person medical visits) and "telemedicine" (remote care delivered via technology). Participants were assigned to different sequences that varied how long they spent in each type of care over a 36-month period. The trial measured whether the virus became undetectable in participants' blood, as well as how many people started a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04798521 · results posted 8 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04798521) enrolled 203 people who had Hepatitis C virus (HCV). Participants were placed into one of two groups: 100 people received "Tele-HCV Treatment" (HCV treatment delivered remotely, such as via telehealth) and 103 people received "Community Linkage to Care" (being connected to existing community health services). The trial was measuring things like whether participants cleared the virus from their blood, whether they started and finished their HCV medication, and whether they engaged with harm reduction services (sup...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03221309 · results posted 3 September 2024
According to the results reported on ClinicalTrials.gov, 198 adults infected with Hepatitis C (HCV) were enrolled in this trial. The study was divided into two phases — 100 people took part in Phase 1 and 98 in Phase 2. Overall, 160 participants completed the trial and 38 did not. The trial was measuring several things at once: whether the Hepatitis C virus became undetectable in participants' blood 12 weeks after finishing treatment (known as a "sustained virologic response," meaning the virus could no longer be detected), how many HIV-negative participants started a medication to reduce the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04042740 · results posted 11 July 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 45 adults in a single group who received a four-week course of a combination medicine called glecaprevir/pibrentasvir (also referred to as G/P) for hepatitis C virus (HCV) infection. The trial was measuring whether the virus became undetectable in participants' blood 12 weeks after they finished treatment — a milestone researchers call SVR12 — as well as how many people experienced side effects and how many completed the full four weeks of treatment. Participants were followed for about 24 weeks after treatment, and t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02292706 · results posted 4 October 2023
According to the results reported on ClinicalTrials.gov, this registry study (NCT02292706) followed 1,609 people across eight groups over approximately 240 weeks (around four and a half years). Each group had previously been treated for hepatitis C (a liver virus infection) with one of several different antiviral medicine combinations in an earlier ("parent") trial. The study was tracking three main things over time: whether participants kept undetectable levels of the hepatitis C virus in their blood, whether they experienced any liver-related health events, and whether they developed a type...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03801707 · results posted 13 September 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 36 people who received a kidney transplant from a donor who had hepatitis C, even though the recipients themselves did not have hepatitis C. After the transplant, participants were given antiviral medicines to treat the hepatitis C they acquired through the donated kidney. The trial was measuring whether the virus could be cleared from the body and tracking a number of other health indicators over time. Thirty of the 36 participants completed the study, with 6 not completing it (the reasons were not detailed in the da...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01226797 · results posted 27 July 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 24 people in total — 12 who received the study drug (called PF-04136309) and 12 who received a placebo (a dummy treatment with no active ingredient). Of those, 10 in the drug group and 11 in the placebo group completed the study. The trial was measuring changes in two liver enzymes — ALT and AST — which are proteins found in the blood that can indicate liver inflammation when they are elevated. The main question the trial asked was how many participants showed a meaningful drop (at least 30%) in their ALT level after...
-
NCT01946516 · results posted 3 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT01946516) enrolled 3,051 people who had recently been diagnosed with cancer and were attending oncology clinics in the United States associated with the SWOG research network. The trial was not testing a treatment — instead, it was designed to measure how common three viral infections (hepatitis B or HBV, hepatitis C or HCV, and HIV) are among people newly diagnosed with cancer. Nearly all participants were tested for each virus, with 3,050 tested for HBV, 2,990 tested for HCV, and 3,045 tested for HIV. The reported data...
-
NCT02219490 · results posted 7 April 2023
According to the results reported on ClinicalTrials.gov, this trial (known as TOPAZ-I) enrolled 1,596 people with hepatitis C who were treated with a combination of antiviral medicines (ABT-450/r/ABT-267 plus ABT-333, with or without ribavirin). Of those, 1,258 completed the study and 338 did not. The trial was designed to track longer-term liver-related health events — such as death from any cause, death specifically related to the liver, the liver losing its ability to function properly (called liver decompensation), liver transplant, and a type of liver cancer called hepatocellular carcinom...
-
NCT01667081 · results posted 6 June 2022
According to the results reported on ClinicalTrials.gov, this long-term follow-up study enrolled 2,435 people in total — 1,909 in a group that had previously received a combination of grazoprevir (GZR) and elbasvir (EBR), with or without ribavirin (RBV), and 526 in a group that had received other GZR-containing treatment regimens. The study was measuring two main things over time: whether the hepatitis C virus (HCV) came back after treatment had finished, and whether certain viral changes — called resistance-associated substitutions (RASs), meaning alterations in the virus that can make it har...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02939989 · results posted 4 May 2022
According to the results reported on ClinicalTrials.gov, this trial looked at a combination of three antiviral medicines — glecaprevir/pibrentasvir, sofosbuvir, and ribavirin — given to people with hepatitis C. A total of 33 participants took part: 5 people received the combination for 12 weeks, and 28 people received it for 16 weeks. All 33 participants completed the study with no drop-outs reported. The main thing the trial was measuring was whether the hepatitis C virus became undetectable in participants' blood 12 weeks after they finished treatment — a result doctors call SVR12, which sim...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02625909 · results posted 24 November 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02625909) enrolled 188 people with a recent hepatitis C virus (HCV) infection. Participants were randomly assigned to take a combination medicine called sofosbuvir/velpatasvir (SOF/VEL) for either 6 weeks (93 people) or 12 weeks (95 people). The main thing the trial was measuring was how many people in each group had no detectable hepatitis C virus in their blood 12 weeks after finishing treatment — a point often called SVR12, which simply means the virus could no longer be found at that time. The reported data shows that...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03781726 · results posted 11 May 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 30 people who had received a kidney transplant from a donor who tested positive for the hepatitis C virus (HCV). All 30 participants were given a fixed-dose combination medicine called glecaprevir/pibrentasvir (also known as G/P). The trial was measuring whether the hepatitis C virus became undetectable in participants' blood after treatment, and whether the virus came back either during or after treatment. Twenty-eight of the 30 participants completed the study, with two not completing it (the reasons were not detail...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03501550 · results posted 28 April 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 12 participants, all of whom received a combination of two treatments: an experimental drug called CDI-31244 together with an existing hepatitis C medicine known as SOF/VEL (sofosbuvir/velpatasvir). All 12 participants completed the trial. The study was measuring two main things: how many participants experienced unwanted side effects (called adverse events) during treatment, and how many had what is known as a "sustained virologic response" — meaning the hepatitis C virus became undetectable in their blood and stayed...
-
NCT03487848 · results posted 20 April 2021
According to the results reported on ClinicalTrials.gov, this trial involved 5 people who received a combination of two antiviral medicines — daclatasvir and sofosbuvir. Four of the five participants completed the study, and one did not finish. The trial was primarily focused on measuring how these medicines moved through the body — specifically, how much of the drug daclatasvir was present in the bloodstream at various points after taking a dose. The reported data shows the following measurements for daclatasvir in the bloodstream: the lowest recorded level (the "trough," meaning the amount...
-
NCT03619837 · results posted 3 March 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 122 people during an initial screening phase, of whom 24 went on to take part in the main study — and all 24 completed it. The trial was measuring what happened to levels of hepatitis C virus (HCV) in the blood of participants after they received antiviral treatment, specifically looking at whether the virus became undetectable at 12 weeks after finishing treatment (a milestone researchers call SVR12). It also tracked whether participants stopped treatment early, and whether both the patients and their transplanted or...
-
NCT02002767 · results posted 16 November 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02002767) enrolled 19 adults in total — 9 with normal kidney function and 10 with severe kidney impairment. All 19 participants completed the study with no dropouts. The trial was measuring how the body processes a medicine called velpatasvir, by looking at how much of the drug gets into the bloodstream and how quickly, comparing the two groups. The reported data shows that people with severe kidney impairment had somewhat higher levels of velpatasvir in their blood compared to those with normal kidney function. Specifica...
-
NCT03093415 · results posted 12 November 2020
According to the results reported on ClinicalTrials.gov, this trial looked at hepatitis C treatment across three different clinic settings in the United States: a medication-assisted therapy clinic (Old Town Clinic), a needle exchange programme (Outside In Clinic), and a hospital liver specialist clinic (OHSU). In total, 350 people were assessed for eligibility across the three sites, and 100 people were enrolled — 25 from Old Town Clinic, 25 from Outside In Clinic, and 50 from the hospital clinic. The trial was primarily measuring how many participants had no detectable hepatitis C virus in t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02441283 · results posted 21 September 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02441283) enrolled 377 people who had previously been treated for Hepatitis C (a liver infection caused by a virus) in an earlier study using medicines that included ABT-493 and/or ABT-530. Of those 377 participants, 287 completed the follow-up study and 90 did not. The trial was designed to track whether people who had already cleared the Hepatitis C virus in that earlier study continued to show no detectable virus over time, and to look at any signs of the virus returning or a new infection occurring. The reported data...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03820258 · results posted 31 August 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 21 participants, all of whom completed the study — none dropped out. The trial tested a single combination tablet containing three antiviral medicines (referred to as SOF/VEL/VOX) in people with hepatitis C. The main thing the trial was measuring was how the body processed the drugs — specifically, how much of each medicine was present in the bloodstream over time (a measurement called "drug exposure" or AUCtau). The trial also tracked whether participants' hepatitis C virus became undetectable in the weeks and months...
-
NCT03089944 · results posted 13 July 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT03089944) enrolled 343 adults with chronic hepatitis C virus (HCV) infection across several different strains of the virus (known as genotypes 1, 2, 3, 4, 5, and 6). All participants received the same combination treatment — glecaprevir and pibrentasvir — taken for 8 weeks. Of the 343 people who started the trial, 331 completed it and 12 did not. The trial was primarily measuring how many participants had no detectable virus in their blood 12 weeks after finishing treatment — a result researchers call SVR12, or "sustained...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02402452 · results posted 20 March 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02402452) involved 20 adults in total — 10 with severe kidney (renal) impairment and 10 with normal kidney function. All 20 participants completed the study. The trial was measuring how a drug called voxilaprevir moves through the body differently depending on kidney function. To do this, researchers tracked the drug's concentration in the blood over time using standard measurements used in drug studies. The reported data shows that participants with severe kidney impairment had higher levels of voxilaprevir in their bloo...
-
NCT02886624 · results posted 29 January 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 30 participants who took a combination treatment called grazoprevir/elbasvir — two antiviral medicines given together — for 8 weeks to treat hepatitis C (HCV). All 30 participants completed the treatment phase. The trial then followed participants for 12 weeks after treatment ended, and again at 48 weeks after treatment. The study was measuring whether the hepatitis C virus became undetectable in participants' blood after treatment, as well as several other things including treatment adherence, HIV-related measures (a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02940691 · results posted 30 December 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 32 people in a single group who all received a combination tablet containing two medicines — grazoprevir and elbasvir — taken once daily for 12 weeks. The trial was measuring whether the hepatitis C virus (HCV) became undetectable in participants' blood 12 weeks after they finished treatment, a point in time often called SVR12. Of the 32 people who started, 26 completed the study and 6 did not. The reported data shows that for the main measure — having no detectable hepatitis C virus in the blood 12 weeks after finis...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03222583 · results posted 23 December 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT03222583) enrolled 546 people who had been diagnosed with the hepatitis C virus (HCV). Participants were split into two groups: 363 people were assigned to Arm A, where they received the active combination medicine glecaprevir/pibrentasvir straight away, and 183 people were assigned to Arm B, where they first received a dummy (placebo) treatment before later switching to the active medicine. The trial was mainly measuring whether the active medicine could clear the hepatitis C virus from participants' blood — specifically,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 191 reported results for Hepatitis C
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, hepatitis C attracts a very large amount of public research investment from the United States, and that level of support has remained broadly steady over recent years. This kind of sustained, substantial commitment from one of the world's largest medical research funders is generally a positive sign for patients, as it suggests researchers continue to see meaningful...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.